TGTX - Earnings call transcript Q1 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to TG Therapeutics' Q1 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jenna Bosco, Senior Vice President of Corporate Communications. you. Thank

begin. may You

Jenna Bosco

Communications, morning first to and quarter Jenna of I Good our you regarding call conference business conference TG am today. Corporate SVP TG's Therapeutics' XXXX Bosco, I and you. welcome our to welcome call update. and Thank financial results

provide antibody, Executive Officer, Michael once-daily will Chairman results, Safe well turn and anti-CDXX inhibitor, Harbor Financial the development Power, our on Weiss, overview Executive of our an Officer, ongoing call TG's Sean our provide Chief of who standings. to of the as an the ublituximab; pre-clinical update novel, umbralisib, then and company and as Company's review Following glycoengineered PIXK monoclonal a Chief over novel, overall statements, will our our financial delta

would next www.tgtherapeutics.com, remarks the and Act TG differ Before listen-only it our conference and expectations, Factors future will these be indicated. from are for Private that may Litigation operation days. where provisions risks available being a recorded found participants XX that is results and everyone subject the to factors may on All on mode. our to call materially various website, include will SEC like rebroadcast forward-looking make risk statements Securities we uncertainties actual we about affect purposes TG's be those can on This remind begin, that Harbor statements this cause that cautions Therapeutics' in filings. audio for call forward-looking our for XXXX. be uncertainties that TG I the to of prospects constitute plans under that Safe of various Reform

Chief as Sean to turn over as to Financial XXXX, the discuss the overall of financial first like the the well would condition. Power, to I for results Officer, company's financial Now, quarter briefly call our

Sean Power

everyone, us. for Jenna, Thank joining thanks, you, and

XX, section be & on you As this the morning investment our million. can released Media equivalents, financial our of cash at receivables cash interest begin had tgtherapeutics.com. and be were I'll our At and cash, viewed with aware, we March may $XXX.X securities of website Investors results position.

position the net as our approximately including of of is XXXX, facility ATM when from quarter of proceeds $XX.X the sales cash of March forma utilization million $XXX.X XXXX. second pro Our XX, million during

per for share, of non-cash compared XXXX, the Our million items, net quarter $X.X to $XX.X our GAAP of operating was was $X.XX a from comparable the of including approximately quarter expenses non-cash we for in loss $XX.X In The commercialization. program. XXXX, for utilized manufacturing quarter for enrolment preparation $XX.X by part in CMC large inclusive and first than clinical stronger of the per activities X of excluding million to net million, driven $X.XX Phase the and loss our during anticipated XXXX, ongoing of million quarter cash XXXX. items, or in potential net first MS $XX into million trials loss X or fund share first Phase approximately

have quarter of and we burn balance the for into Accordingly, during filing goals, are bit first we XXXX. well-positioned that million gap. first $XX of the our our expenses pre-commercial added should stable the the the through our of end use over while the relatively remainder we to remain on a year, sheet clinical to this remain second deliver year To filling expect Our we approximately ATM. the expenses ensure increased and expected and half toward [ph] could slow cash next of expenses BLA/NDA

that, and operations raise Inclusive now second current will Executive to I sufficient over the Our our approximately CEO. XXXX. our turn cash first during of the believe average this $XX.XX, we price our position were Weiss, campaign With shares during Chairman to and the fund total quarters, is cash be million. will Mike issued capital and call well $X into

Michael Weiss

the and for and this programs. preclinical you, final plus for X our our the response decisions own enrolment updates and thanks XXXX UNITY-NHL highly is as pipeline morning. UNITY-CLL trial, potential the MS well everyone from with program, significant be XXXX data Jenna, company’s of as look cohorts as of joining topline to BLA/NDA Phase Sean BTK up year. a we is us the forward current in X announcement later in of X include extension inhibitor, of our study, first Thank to the a MS rate great into Phase our impactful various year of off the start Phase clinical setting data, filing to filings to the completion enrollment

the program. as program, would for development achieved current the our Hengrui In to inhibitor. agreement in reviewing call XXXX, as recapping to the first-in-human February, referred well milestones of our we license with the inhibitor their some PIXK Lancet that the TGR-XXXX, from my this X, rights develop like entered into The umbralisib, of once-daily results In accomplishments of of key as to our a Company, for Pharma Phase formerly we Oncology, the BTK Before Chinese study XXXX. kick publication we delta already recent first have announced January, I novel

forward we year. beginning, that, as high-level overview to give and and a brief formerly not long most the at me will and our pivotal Annual of We’ve continuing updated ago. for Meeting. recently, ublituximab, presented preclinical XXXX And as at look inhibitor, TG-XXXX, of presented busy programs data novel the MS the the let With the Phase Research of Association referred conference BET build Academy our X annual our that call ongoing to Cancer start meeting. to to and American the we keep quarterly momentum to the Neurology throughout a year, it is first Phase but TG-XXXX trial last MRI had X was clinical we this the try just from Next, American on today we data

in study UNITY-CLL we the plus begin Let’s chronic and as with patients which control umbralisib leukemia. both a treatment-naïve chlorambucil or randomized in combination active ublituximab UX compared with to or combination to is the lymphocytic with refractory of Phase refer program, of X relapsed ublituximab an

this conducted Enrolment the As this including months X trial frontline of and or Approximately last and a a refractory. patients. and FDA global the schedule. is XX% assessment of over is enrolled XXX enrolled being protocol exceeded trial, approximately patients our with over nearly under trial large into trial reminder, the special the expectations ahead XX%

overall from second the trial quarter are freight year. this targeting We still topline this response data in of

seek update survival the successful, XXXX. summer. give patients up broad last results would rate, study may remind do ideally we on end quarterly a if the approval for However, reminding which for of occur approval treatment accelerated support to trial. call, the we as of quarter we that, slightly on CLL. in primary is to wait choose to the to It To is we to endpoint the worth also improvement response and plan the we GENUINE to very still I’ll label announcement our the quick have if of XX% are of everyone, fourth With for in absolute supported conference file UX a and this full expect progression-free of everyone for that this, combination mentioned the longer on targeting follow overall before the topline

ublituximab patients Phase reminder, randomized ibrutinib GENUINE is Leukemia. to in high-risk X Lymphocytic monotherapy compared Chronic plus relapsed of a with or ibrutinib, trial As a refractory,

available through We working including benefit preparation are we the forward the BLA venetoclax potential meaningful supporting results assessment, based risk-benefit with CLL to provides supports moving data. third quarter rate BLA/NDA experts with therapy, of response currently this ibrutinib this also we our all over preparation year, position potential which closely should filing, ublituximab, of therapy. believe critical finalize will the UNITY-CLL parallel, based In in on our in which of knowing at are the filing be be overall the

update I’ll UNITY-NHL trial. you our a short Next, give on

As currently using of you or trial be distinct UNITY-NHL umbralisib this subtypes non-Hodgkin evaluating the triple may as evaluating three towards potentially of of combinations subtypes backbone combination The across single-agent UX NHL. evaluating NHL. is a and a multifaceted has program UX different aware, lymphoma the double various cohorts, building

with refractory enrolling same the currently monotherapy. let’s Follicular cohort. Lymphoma are this or umbralisib we start patients of arm a cohort, So, into relapsed follicular first In

this to patients XXX plan approximately enroll is and XXXX. achieve made goal by to Our

a designed and As similarly panel reminder, study. sized a the listed approved with was from data the recently

Next. The patients are refractory marginal follicular, we the a into umbralisib cohort. monotherapy. Similar zone of relapsed enrolling to also or arm single currently

achieve are based following and Our and plan on this sized the in here which reminder, about XX goal ibrutinib a approval, we as we ibrutinib, XXXX. quarter to a the the study. fourth Again, recent of is designed to here is similarly enroll patients

lymphoma. B-cell bendamustine. of we patients evaluating single enrolling are we aggressive trial, into relapsed UNITY-NHL diffused more the of a now is within or lymphoma with refractory large plus of UX cohort arm form a and are a Lastly, This

enrollment plus targeting complete We into UX also by are mid-year. benda the cohort

the patients in approved let’s through enrolled of a chose all remained efficacy Phase those academy B-cell include annualized data only Now, now – depletion, has well-tolerated and remains XX below the previously Phase through the affirm neurology ublituximab from relapse patients, the TX X meeting. ocrelizumab, program. for Multiple of Gd-enhancing importantly, data ARR XXX most of safety updated weeks Phase treatment, across rate to the including also American one which monoclonal presented for hour now the of antibody XX all we with most ublituximab With and dose reduction rapid XX annual XXX mg Starting as is observed mg with in that program. updated as receiving weeks X the MS, all sustained MS. review data which an presented dose, low infusion patients The the dose our the with and XXX% recently data at anti-CDXX ublituximab Sclerosis was lesions, of X continues

major forward the Sclerosis XX-week on data We are enrolled patients which meeting will data to supports look pleased Multiple ongoing trials. X and final This data a X as known this program include Phase our in at all year. the extremely Phase later presenting ULTIMATE

tracking a quarter identical ocrelizumab, protocol and the CDXX With where MS to of the its I’d trials special session. to under complete the we reminder, are us approximately are are Q&A on in compete first major The like a in the XXXX. evaluating we first price for we believe call this sales with opportunity the only enrolling patients With by turn year, ublituximab in both the begin over approximately currently two trials XXX enrolment targeting X two and we to United can MS. the operator convenience. relapsing generate billion conference As to and assessment running States forms approved FDA for of across represents Europe, the X that, trials of in Phase

concluding remarks, our remaining well some provide which, Following and as as I XXXX. return will milestones for review

Operator

Thank SunTrust you. is Our from go Instructions] question Suneja coming ahead. Yatin first [Operator of Please Humphrey. Robinson

Yatin Suneja

decision, Mike, Good unblind that guys. and Thanks all you I data, sure on tell progress. able comment you look for am feedback you morning but come? blinded when on data decision are the just question blinded taking could when trying basis on just the will you your understand at are not of congrats much, to getting my might would you from the to and experts When the that to it? make the

Michael Weiss

is say terms in not on guidance that the of I would as of important. timing Yes. expert

months from X to enough XX more all that to not months. Substantially a our majority. moving not X has partnership trials that built Like will a it know is is likely now the – estimate. I over I XQ months. an from and [indiscernible] responses to nine I will large be few clinical have note XX think data – the mean is It months be major number, follow by X a X seen been vast It and already into it responses. we said, to a little prior

and think the out conversation So, said reached the I and and days extra extra advice there up more shareholders from reach this [indiscernible] XX for any our last don't advices responders. since wait XX, just I few we those quarter pick who had of come is expert think out

haven't next will leaning we So, or made XX decision, a where in keeping it a getting to several it the direction, that think won’t our open, few, we weeks I material making yet, certainly though a because not we're that is made occur yet, it and for responses of probably final that way, be decision the but – will close decision options be again cycles. either and still but are think would a we're between sure be X sometime so, in we I haven’t probably handful

Yatin Suneja

then chemo And occur control it. this arm, time got is that less probably phenomenon immunotherapy of the Okay, to correct? deeper over responses on likely

Michael Weiss

Yes.

is very other the good the that’s side So coin. point. a of It

the since time response, so following stopped, carrying the XX not likely and X-month treatment likely, patients for treated arm, stopped patients control would basically and and those a that see be is to late months for at the months you in so it X the optimal onset forward responder So, months are patients to are X dosing, the response X are group. that not the

thing The would is have on that those follow-up other important we additional be patients. too will

So, particularly sure, control arm, but control the the in all the for for again, arm. patients in mostly patients but

of case, and some little would If GENUINE up confirmation you open the there that be In with to this bit have noted not responses possible a earlier some responses responses study, say and needed recall did of able be arm still were we not know will we you we that verified. the the XXX% control confront. conformed it part for is I or to be those most confirmed would that

advantage the these types shorter alone we think cycles, we those late-onset our progression those drug and feel open we to it types chemo-based the are I drugs, with conventions, – typically not shorter CDXX are responses antagonists. longer BCR or with responses. antagonists our lived, do of is And free combination, than but typically BCR later because of go putting on why survival just the is regimens So, which we that of with cycles aside know in longer responders XX X see whether it we

again think incrementally start the up around it the I better, margins again is once it far. pushing So, longer probably goes but you [indiscernible] too

Yatin Suneja

question Maybe the just it. Got one on more enrolment UNITY criteria.

that might trial assumption be and able patients? us is perform how to If the So, you I any that help so just case, could control-arm patients? what are maybe the mutation, not high-risk screening and high-risk all understanding lines open where your our to that the particular might is understand think those is enroll you for Thanks. you percent in for

Michael Weiss

was trial experience is all what Yes, an would describe, trial. really think the a I it people so real-world comer, I most describe would

the anyone door, will take and who that a So, the much you it up it was primarily would think learned in that in was, have we pretty shows setting know and of expect community we at sort XX% GENUINE to what high-risk that, from ought ordinary risk-patients, patients category. some probably and the was of and normal distribution I be of in patients between XX% our high-risk we and trial somewhere

high XX%, a and it in done about, sure it of XX% for pretty protocol In screened don't We published have at screening between a that’s I would data, where X% I frontline is and the setting, setting have patients came features. but that think would the relapsed/refractory the XX-Qs. XX% risk include qualify [indiscernible] high-risk probably

but high-risk it not come down patients has zero, it the expectation a risk performance certainly yeah, treatments in ordinary lower a than in bit. So, patients, quite – the expectations chemo-based is for is of the a been

BR overall is trial, [ph] the specifically were piece, and ibrutinib-BR randomized where we’ve like referred where rate the versus case to that response particular XX alone patients to XX% and excluded So, the there. HELIOS

I setting would plus expect lower in response So, rate this chemo patients. we think for a those CDXX,

Yatin Suneja

it. Got

Just following last question. up, I promise,

academics? also, of that frontline, you and tell you terms environment for both percent oral and split might split And what academic you similar and community us center? category it across economy in the relapsed/refractory in said community Thanks. or is high-risk So, of be could about what sort UNITY-CLL, was

Michael Weiss

patients I that very terms of community-based in in percentages clear came to U.S. in advantage the centers. what on unfortunately but relapsed/refractory. the on if community was enrolment, reflection the exact certainly I have participation community it a know don't a we think academics, and don't versus of exact, and distribution the based Yes, the large overall is I just had frontline there in trial, again versus any had

Yatin Suneja

again congrats you Thank much, so all all progress. I the have. That’s and Great. on

Michael Weiss

Yatin. Appreciate Thanks, it.

Operator

Thank you.

is ahead. of Kaplan Ladenburg question Matt Thalmann. from next Please Our go coming

Matt Kaplan

Hi good guys. morning

Sean Power

morning. Good

Matt Kaplan

the on progress. Congrats

obviously on Just should PFS out? to is to read endpoint understand UNITY-CLL. terms study, that bit focus for the the your we for endpoint, a little of more expect in that timing when us Help primary

Sean Power

ball Yes. answer, I a able really crystal had That’s a I a to good If unfortunately I’d you don't. Matt. good question give be

pretty better guess have what and we the been certainly of say part we So, of that think when we a guestimate into where I distribution best curve that’s today XXXX as out, put today our tail of year towards best PFS we’ve will the move we to normal [ph] is for latter I much a will over our saying this possibilities XXXX, XXXX, part sense but think would tail end the are. [ph] read of little of and

We sometime association what we the in, and guidance that a PFS have in, of think will events events have around we ASH, sense a meeting that when our the in possibly the how end of some little clarity will we readout. with the could are rate coming coming provide of perhaps good of analyst more year, hopefully bit so the on

Matt Kaplan

Very good.

Okay. shifting you for the on moving a then can clinic? a your the in after discussion terms give And BTK UNITY-CLL, to all pipeline timeline the into bit, inhibitor us sense of little

Sean Power

has trial so We know we and. are the get in My The is in good will news. into here crossed, next Yes. extremely that the been clinic the occurred, working first-in-human so hopefully China, teams started in so few fingers have has months clinical hard. certainly

few the start, own like I first-in-human will Our in hopefully months. said, next

a dedicated foreign, program, potential translating IND real Chinese pretty to other U.S, is just logistics particularly honestly, just every it in of know the have and and three you primarily come this all filings, has it no should BLA to over UNITY that it next I again two, had we There on, resources but together a are to the over than time close. takes months. time putting We we preparations first-in-human and take have for have been little GENUINE, the issues time done bit on think

Matt Kaplan

for Great. questions. taking the Thanks

Sean Power

welcome. Yes, you're

Operator

you. Thank

James. of Our next question Benjamin go is Raymond Please coming Reni from ahead.

Reni Benjamin

Hi, the guys. good morning for Thanks the questions. taking

Michael Weiss

Reni. Hi,

Reni Benjamin

number Can usually even you with that the is pushing it me I an SPA, is clear-cut that and that is, impact changing, UNITY of does plan Mike, a anyway I SPA? FDA that and is is remind imagine all does based with imagine the under on HI. events filed in if responses and stats it there

Michael Weiss

Right.

do SPA is So, an have correct. we that

is PFS the a PFS matter follow-up So, this patients gets numbers months the you analysis as get events so so actually event the in to to plan overall response, risk says, long to greater patients the on or driven, since up. think open six SPA. respect could With it of us as don’t and satisfied you with are I we analysis, an

we again, have So, some we think flexibility.

and in we have cautious everything being we what with now are do is We to certainly careful make that okay sure FDA. checked the

I but it response, effect event we up the no that. are driven when don’t event is certainly there do being not overall driven, driven – from the we we is So, and and cautious that we and patient and it, stuff open the and certainly be doing PFS how so more would

Reni Benjamin

DSMB there any and our have, even your the statistical to six the months, us, Got just DSMB paid? responses, penalty a can it. that And first you every sort I from of remind after look or guess taken you is it so be three every is months or is needs meeting then perspective, for

Michael Weiss

penalty, statistical the beginning. from was alpha again, very the No allocated we ORR

plan. the So, is analysis part of it statistical

again difference response. saw that said allocate alpha what to did we’ve powerful at analysis XX% alpha we that we overall some to XX% in that and So, power the show with is allocated

Reni Benjamin

And the then it. meetings. Got DSMB just

Michael Weiss

plan response to and do I but do [indiscernible] check assume to the think the it X meetings, analysis I is check at next that. of overall team, X when DSMB and point as is we so. will part every the with is will the occurs I My months that next or probably guess DSMB to have we DSMB that the months this

Reni Benjamin

might can just another price? in how it think, about of inhibitor that all you you you been guess primarily talk that with I and the the a become there of just one final bit different kind have ideally feel that’s option the how it developed landscape? And one kind from where little me, it. BTK fit BTK out than could Or in does so others well, Got compete this inhibitor, is

Michael Weiss

I extent. So, is I mean, think latter certainly true to the certain

in about competing we So, us for could combinations. just building it’s be price, out there but more

we’ve UX areas. data some across of disease really multiple So, plus seen strong umbralisib

approved BTK competing will it as So, the how option it’s should or we developing time. the in it at a that that other comes that’s, patients, a with again, there attractive or the combinations be about fruition three real do package clinic the I UX think, not a very next there combination if be I and excitement The preclinical think four is profile may but into head-to-head to potential forward. we BTK’s or going out acquire for

owning obviously to every resources, extent the we believe still that the the certainly So, [indiscernible] desire we – is pipeline. the are have build-out important have so and continue to mechanism to we we

just agent think and makes we got That out the in I was BTK integrates up PDLX PDLX, how within lots quad we we’ve it certainly that think of portfolio always these So, what know for that making combination continue strategy BTK I UX a it don't happens, way continues of plan do a the opportunities of we part be our BTK pricing with BTK and sense to just or I it’s of see through sorted focus that building created combinations. is sure plus, to better come these in UX that plus whether have a active is or room but that the be creativity, perhaps options, think you as ways our had, even [indiscernible]. as is, there, there BTK single to we sort do combinations price again

Reni Benjamin

and questions taking for good Thanks luck. the Perfect.

Michael Weiss

Reni. Thanks,

Operator

you. Thank

Madhu ahead. FBR. of Our go B. next Kumar from question Please coming Riley is

Madhu Kumar

Okay.

any of the kind for thanks there timing that Thinking key ORR of the ORR question. aspects responders picking besides are up the about readout, of readout? are UNITY-CLL taking the additional the for So, considerations

Michael Weiss

I FDA, so. of had all We’ve mean and setting think tolerability. is overall not better around are around having that’s good gives response multiple for them UNITY-CLL, on long-term information really, multiple but our and additional think with follow-ups, for programs on follow-up meetings gives thing. don't a – they I duration information I more pushing the better just of and which

and weighing then certainly are a better to longer in So, information those factors we're we have believe that decent across all it board. is follow-up done the is it

about days provides incremental it’s which of thing and of some like duration concept pretty overall that, better modest it’s So, of also not I their that advantage the why just providing XX potentially follow-up and is but information. not is more a is good just it advancing of again tolerability take and information said XX, overall long-term response, response

Madhu Kumar

in of experts you of of CLL following space choice? a when key terms for is duration them that, response to speak drug the consideration So, from

Michael Weiss

Yes.

I think anytime you you of things see are one looking at right. response two to rate want overall

or response. little relatively in see, it it’s don't of if have kind duration comparable modest act, greater want to you duration to to something, You to comparing improvement bit is you're modest to which of going balancing response duration response. or response your And want see a longer overall improvement see or if a want a you a

if them duration comparable I you many only more, improve just improve in Likewise, going by if response fine. expert if then free double in take and benefit is of a you magnitude particular response see a how the but data, the to how and larger PFS. say, would the duration concept is think other you overall can a same of opinion don't filed reversely look also increase the applies a but is survival. think give to that response people people response might I sort PFS as twice at I of overall duration progression are have in you of you improve there than to modest you large If response balance a [indiscernible] the you're amount, you going between any

Madhu Kumar

questions. Great. Thanks taking right. All for my

Michael Weiss

problem. No

Operator

ahead. coming [Operator question Andrews next go is Instructions] Please Jefferies. Our from of Matthew

Matthew Andrews

Hi, good Mike. morning

follow-up what I through go Just can spend UNITY-CLL, ORR mind full in need PFS you the a on process that’s can't into just you primary specifics, you statistical to in UNITY-CLL the a to response thought and and but know study? just thought allocated get questions PFS the U.S. your ultimate with because you walk talk that the you is to for versus endpoint alpha is such related the approval bearing how us Can process through unique

Michael Weiss

Yes.

the candid not know want important for have have to of for we be live to may going up So, the to – that’s most that’s patients, look been important we pretty they going for longer. endpoint progression that’s as the you be allocated to most [indiscernible] most survival important they that free alpha the most the FDA, endpoint endpoints prescribers and

because wanted is again alpha we that point appropriate setting obviously clearly, of the because to have amount get of the respect sure but a to context make have this So, we so To to we in it that we have overall allocated end patients power lot a response important, the of XX% the involved. we many to do binary that. patients most a with study firm in to outcome

the So, of allocated net the alpha PFS the there we’ve bulk to effect is the again I think endpoint.

response. number overall lost patients XX% power We for that of that given go the enough we that maintain have XX% just have alpha

Matthew Andrews

on a with where Europe? CHMP file clinically do there improvement assuming in meaningful Thanks. and UNITY-CLL could statistically you rate response response you. significant Thank are you Okay. is think discussions And the based that option

Michael Weiss

file to think is possibility the Sure. we there Matt. Thanks Yes, so certainly Europe. in

data I that. will think on we working once we certainly get the start

the with and spent that haven't with it. its FDA our the of time today, working spend FDA lot a time on with working we in time trial closer We this most of on

So, we the think hand get on of the filings think in data will filing. that, let’s and we U.S. the top global about

Matthew Andrews

Thank you. it. Got

Michael Weiss

Thanks Matt.

Operator

closing or over the this to Thank like comments. Weiss At I’d Mr. time, floor turn back additional any to you. for

Michael Weiss

for to key again you chronic and is UNITY-CLL Obviously, and one joining the and I data once XXXX. by aware top goals Q&A everyone up big overall just today's UX, us line leukaemia. our is on thank the would based from response like Phase for today. Again, reviewing Great, of up trial. frontline be everyone again, this the coming call that refractory thanks and objectives last our presentation would versus ublituximab on for the umbralisib the wrap remainder rate the X lymphocytic of

prepared the the in company's mentioned BLA/NDA remarks end year. finding before file we the as also, We of are first to this preparing and

are X ublituximab the trial again I ongoing we forward which zone again with the data margins and results finally currently that those year, studies, is in not forward X present, would updated our cohorts and on if final that to enrolling present completing again pushing follicular the So, forward compare see, for the Phase Phase results this able results think something all, okra. to enrolment are plan in I’m oncology MS from looking to trial and final results later from so we to We [indiscernible], look we focusing that. UNITY-NHL clinical the and we current-arms to be

well. So exciting interesting as that would be and

us. who to of have behalf thank patients worked with on thank the would been our and supportive who us, shareholders just of at closely all investigators we all TG, joined the very who like have again, of particularly of So us have trials our

for great joining a So, have everyone again and us thanks day.

Operator

for you participation. Thank gentlemen. your and Ladies

this lines at and your day. a You time may wonderful have disconnect

TG Therapeutics (TGTX) 8 May 182018 Q1 Earnings call transcript